Characteristics of men using non-prescription medicines to treat their lower urinary tract symptoms
From BPH to male LUTS: a 20-year journey of the EAU guidelines
Diagnosis and Therapy of Female Urinary Incontinence. Guideline of the DGGG, OEGGG and SGGG (S2k-Level, AWMF Registry No. 015/091, January 2022)
Diagnosis and Therapy of Female Urinary Incontinence. Guideline of the DGGG, OEGGG and SGGG (S2k Level, AWMF Registry No. 015/091, January 2022)
Konservative und medikamentöse Therapie des benignen Prostatasyndroms
What Are Realistic Expectations to Become Free of Overactive Bladder Symptoms? Experience from Non-interventional Studies with Propiverine
Factors Associated with Decisions for Initial Dosing, Up-Titration of Propiverine and Treatment Outcomes in Overactive Bladder Syndrome Patients in a Non-Interventional Setting
Impact of early vs. delayed initiation of dutasteride/tamsulosin combination therapy on the risk of acute urinary retention or BPH-related surgery in LUTS/BPH patients with moderate-to-severe symptoms at risk of disease progression
[Use of synthetic slings and mesh implants in the treatment of female stress urinary incontinence and prolapse : Statement of the Working Group on Urological Functional Diagnostics and Female Urology of the Academy of the German Society of Urology].
The International Continence Society (ICS) report on the terminology for adult male lower urinary tract and pelvic floor symptoms and dysfunction
A Comprehensive Review of Overactive Bladder Pathophysiology: On the Way to Tailored Treatment
Terminology report from the International Continence Society (ICS) Working Group on Underactive Bladder (UAB)
Latest Evidence on the Use of Phosphodiesterase Type 5 Inhibitors for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia
Ultrasound detrusor wall thickness measurement in combination with bladder capacity can safely detect detrusor underactivity in adult men
Bladder Instillation Therapy With Hyaluronic Acid and Chondroitin Sulfate Improves Symptoms of Postradiation Cystitis: Prospective Pilot Study
Nocturia is often inadequately assessed, diagnosed and treated by physicians: results of an observational, real‐life practice database containing 8659 European and <scp>US</scp> ‐American patients
Efficacy and safety of tadalafil 5 mg once daily in the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia in men aged ≥75 years: integrated analyses of pooled data from multinational, randomized, placebo‐controlled clinical studies
The Underactive Bladder: A New Clinical Concept?
Appropriateness of oral drugs for long-term treatment of lower urinary tract symptoms in older persons: results of a systematic literature review and international consensus validation process (LUTS-FORTA 2014)
Unravelling detrusor underactivity: Development of a bladder outlet resistance—Bladder contractility nomogram for adult male patients with lower urinary tract symptoms
Detrusor underactivity in men with lower urinary tract symptoms/benign prostatic obstruction
Metabolic syndrome and benign prostatic enlargement: a systematic review and meta‐analysis
Long-term Safety and Efficacy of Single-tablet Combinations of Solifenacin and Tamsulosin Oral Controlled Absorption System in Men with Storage and Voiding Lower Urinary Tract Symptoms: Results from the NEPTUNE Study and NEPTUNE II Open-label Extension
Cardiovascular and ocular safety of α<sub>1</sub>-adrenoceptor antagonists in the treatment of male lower urinary tract symptoms
Nocturia: state of the art and critical analysis of current assessment and treatment strategies
Consistent and significant improvement of nighttime voiding frequency (nocturia) with silodosin in men with LUTS suggestive of BPH: pooled analysis of three randomized, placebo-controlled, double-blind phase III studies
Detrusor contraction power parameters (BCI and W max) rise with increasing bladder outlet obstruction grade in men with lower urinary tract symptoms: results from a urodynamic database analysis
Time to Onset of Clinically Meaningful Improvement with Tadalafil 5 mg Once Daily for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: Analysis of Data Pooled from 4 Pivotal, Double-Blind, Placebo Controlled Studies
Treatment satisfaction with tadalafil or tamsulosin vs placebo in men with lower urinary tract symptoms ( <scp>LUTS</scp> ) suggestive of benign prostatic hyperplasia ( <scp>BPH</scp> ): results from a randomised, placebo‐controlled study
Effects of tadalafil on nighttime voiding (nocturia) in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a post hoc analysis of pooled data from four randomized, placebo-controlled clinical studies